Fluorescence-activated cell sorting (FACS) analysis using Flp-In CHO/hFSHR in comparison to the parental Flp-In CHO cells as specificity control

Fluorescence-activated cell sorting (FACS) analysis using Flp-In CHO/hFSHR in comparison to the parental Flp-In CHO cells as specificity control. pattern of FSH323 staining noticed for ovarian, prostatic, and renal adenocarcinomas indicated that FSHR was expressed mainly in the peripheral tumor blood vessels. Conclusion: Of all published IHC antibodies tested, only antibody FSHR323 proved suitable for target validation of hFSHR in an IHC setting for cancer. Our studies could not confirm the previously reported FSHR overexpression in ovarian and prostate cancer cells. Instead, specific overexpression in peripheral tumor blood vessels could be confirmed after thorough validation of the antibodies used. Keywords: antibody validation, cancer marker validation, FSH, FSHR, immunocytochemistry, immunohistochemistry, kidney cancer, ovarian cancer, prostate cancer 1. Introduction Follicle-stimulating hormone (FSH) is an important hormone responsible for growth, maturation and function of human reproductive system. In females, FSH in the ovaries is involved in folliculogenesis; it induces maturation of ovarian follicles and production of estrogen [1]. In males, FSH in the testes stimulates Sertoli cell proliferation, and supports spermatogenesis [2]. FSH is a glycoprotein heterodimer that binds and acts through the FSH-receptor (FSHR), a G-protein coupled receptor. FSHR possesses the distinctive CLG4B pattern of seven transmembrane Misoprostol spanning domains. Its large extracellular domain (ECD) places it in a specific subgroup together with luteinizing hormone receptor (LHR) and thyroid stimulating hormone receptor (TSHR). This receptor domain is responsible for the high-affinity binding of hormones [3,4,5]. In adult humans, FSHR is expressed mainly in the granulosa cells of the ovary and the Sertoli cells of the testis [3]. It is minimally expressed by the endothelial cells of gonadal blood vessels [6,7]. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses have shown, unequivocally, that FSHR is transcribed in extra gonadal tissues as well, particularly in the human female reproductive tract and the placenta [8], in benign prostatic hyperplasia [9,10,11], prostate cancer [9,10,11], and ovarian cancer [12,13,14]. The focus of this study was to evaluate FSHR as a therapeutic target for ovarian, prostate, and renal cancer. A number of studies indicated FSHR as an attractive target, because of its lack of expression in healthy tissue (despite the above-mentioned expression in the reproductive tracts) and overexpression in malignant ovarian and prostate cancerous tissues [15,16,17,18]. However, divergent immunohistochemical findings have been reported for the FSHR protein expression and localization [10,12,15,19,20,21,22]. Unfortunately, in a number of the expression studies published, the immunohistochemistry (IHC) antibodies used were not indicated, or are no longer available. Three different antibodies have been frequently used to study, immunohistochemically, the expression of FSHR in human tumors: sc-13935 [23,24,25,26,27], sc-7798 [27,28], and FSHR323 [15,20,21,22,29,30], and are claimed to be Misoprostol suitable tools for immunohistochemical evaluation of cancer tissue. These antibodies were commercially validated and obtained because of their suitability to detect FSHR expression in various tissue. Furthermore, because it is normally challenging to recognize monoclonal antibodies you can use as equipment for validation of recombinant proteins antigens or cell lines, we utilized anti-human FSHR Ylanthia? antibodies elevated against two different peptides from the hFSHR ECD (aa295-332). Materials produced for specificity examining from the antibodies included: FSHR extracellular domains provided in virus-like contaminants (VLPs), aswell as cells expressing hFSHR stably, that have been validated because of their surface appearance of useful hFSHR. Furthermore, different cancers cell lines reported to endogenously exhibit hFSHR have already been examined. These Misoprostol included the ovarian cancers cell lines OVCAR-3 [31], and Caov-3 [32], aswell.